What is the share price of Thyrocare Technologies Ltd (THYROCARE) today?
The share price of THYROCARE as on 27th May 2025 is ₹1013.40. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Thyrocare Technologies Ltd (THYROCARE) share?
The past returns of Thyrocare Technologies Ltd (THYROCARE) share are- Past 1 week: 4.51%
- Past 1 month: 14.49%
- Past 3 months: 39.75%
- Past 6 months: 1.37%
- Past 1 year: 63.35%
- Past 3 years: 47.15%
- Past 5 years: 98.49%
What are the peers or stocks similar to Thyrocare Technologies Ltd (THYROCARE)?
The peers or stocks similar to Thyrocare Technologies Ltd (THYROCARE) include:What is the dividend yield % of Thyrocare Technologies Ltd (THYROCARE) share?
The current dividend yield of Thyrocare Technologies Ltd (THYROCARE) is 2.07.What is the market cap of Thyrocare Technologies Ltd (THYROCARE) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Thyrocare Technologies Ltd (THYROCARE) is ₹5381.85 Cr as of 27th May 2025.What is the 52 week high and low of Thyrocare Technologies Ltd (THYROCARE) share?
The 52-week high of Thyrocare Technologies Ltd (THYROCARE) is ₹1055 and the 52-week low is ₹571.40.What is the PE and PB ratio of Thyrocare Technologies Ltd (THYROCARE) stock?
The P/E (price-to-earnings) ratio of Thyrocare Technologies Ltd (THYROCARE) is 58.81. The P/B (price-to-book) ratio is 10.20.Which sector does Thyrocare Technologies Ltd (THYROCARE) belong to?
Thyrocare Technologies Ltd (THYROCARE) belongs to the Health Care sector & Hospitals & Diagnostic Centres sub-sector.How to buy Thyrocare Technologies Ltd (THYROCARE) shares?
You can directly buy Thyrocare Technologies Ltd (THYROCARE) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Thyrocare Technologies Ltd
THYROCARE Share Price
1,013.400.21% (-2.15)
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
THYROCARE Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 58.72 | 10.20 | 2.07% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.25 | 6.48 | 0.85% |
THYROCARE Analyst Ratings & Forecast
Detailed Forecast 100%
Analysts have suggested that investors can buy this stock
from 2 analysts
Price Upside
Earnings Growth
Rev. Growth
THYROCARE Company Profile
Thyrocare Technologies Limited is a diagnostic chain company which offers a range of medical diagnostic tests and profiles of tests that center on early detection and management of disorders and diseases.
Investor Presentation
View olderTHYROCARE Similar Stocks (Peers)
Compare with peersMAXHEALTH
PE Ratio
106.09
1Y Return
44.17%
Buy Reco %
75.00
APOLLOHOSP
PE Ratio
113.55
1Y Return
19.10%
Buy Reco %
86.21
FORTIS
PE Ratio
69.06
1Y Return
54.95%
Buy Reco %
100.00
PE Ratio
45.67
1Y Return
40.91%
Buy Reco %
66.67
MEDANTA
PE Ratio
67.36
1Y Return
1.05%
Buy Reco %
71.43
THYROCARE Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
THYROCARE Stock Summary · April 2025
Thyrocare Technologies Limited demonstrated robust financial performance in Q4 FY '25, achieving a 20% year-on-year revenue growth driven by strong contributions from its pathology and franchise businesses. The company reported a normalized EBITDA of INR 101 crores, reflecting effective cost management and operational efficiencies, despite challenges from recent acquisitions and increased receivables. Management's strategic focus on expanding its franchise network and enhancing diagnostic offerings, particularly in health tech, positions it favorably for future growth, with expectations of mid-teens revenue growth for FY '26. Additionally, the commitment to quality and innovation, underscored by its NABL accreditation, reinforces its competitive edge in the diagnostics market. Overall, the outlook remains optimistic, supported by a stable cash flow and a cautious approach to acquisitions.
Key Points on Thyrocare Stock
THYROCARE Stock Growth Drivers
6Quality and Accreditation Achievements
Thyrocare Technologies Limited has achieved NABL accreditation across all its labs, making it India's first
Operational Efficiency and Growth in Testing Volume
The company reported a significant operational efficiency with an average report turnaround time of 3.43
THYROCARE Stock Challenges
3Deferred Tax Provision Concerns
The company initially set up a deferred tax provision due to impairment concerns related to
Revenue Composition and Dependency Issues
The revenue composition of the company has shown a decline in the share of Aarogyam
THYROCARE Forecasts
THYROCARE Forecast
Price
Revenue
Earnings
THYROCARE Share Price Forecast
2025
Current
₹1,013.40
Baseline
Forecast for May 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹1,013.40
Baseline
Forecast for May 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
THYROCARE Company Revenue Forecast
2025
Current
₹702.18
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
2025
Current
₹702.18
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
THYROCARE Stock EPS (Earnings Per Share) Forecast
2025
Current
₹17.13
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹17.13
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
THYROCARE
Income
Balance Sheet
Cash Flow
Annual Normal View
THYROCARE Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 316.63 | 379.32 | 413.52 | 441.44 | 507.05 | 618.11 | 536.27 | 581.64 | 702.18 | 702.17 | ||||||||||
Raw Materials | 81.78 | 94.61 | 110.79 | 117.17 | 163.86 | 170.57 | 163.03 | 166.98 | 498.43 | 498.42 | ||||||||||
| Power & Fuel Cost | 6.35 | 6.68 | 7.77 | 8.69 | 7.64 | 8.40 | 10.70 | 10.15 | ||||||||||||
| Employee Cost | 32.00 | 35.34 | 43.35 | 48.92 | 58.07 | 61.13 | 106.15 | 107.86 | ||||||||||||
| Selling & Administrative Expenses | 46.14 | 49.57 | 59.27 | 44.48 | 42.16 | 45.47 | 52.69 | 73.23 | ||||||||||||
| Operating & Other expenses | 50.17 | 27.59 | 27.50 | 48.01 | 51.70 | 67.74 | 71.57 | 74.90 | ||||||||||||
EBITDA | 100.19 | 165.53 | 164.84 | 174.17 | 183.62 | 264.80 | 132.13 | 148.52 | 203.75 | 203.75 | ||||||||||
| Depreciation/Amortization | 18.05 | 20.10 | 26.17 | 31.91 | 30.28 | 33.87 | 38.71 | 47.01 | 55.26 | 55.26 | ||||||||||
| PBIT | 82.14 | 145.43 | 138.67 | 142.26 | 153.34 | 230.93 | 93.42 | 101.51 | 148.49 | 148.49 | ||||||||||
| Interest & Other Items | 0.46 | 0.44 | 0.61 | 1.85 | 0.87 | 3.21 | 4.83 | 5.53 | 3.05 | 3.05 | ||||||||||
| PBT | 81.68 | 144.99 | 138.06 | 140.41 | 152.47 | 227.72 | 88.59 | 95.98 | 145.44 | 145.44 | ||||||||||
| Taxes & Other Items | 38.83 | 51.71 | 52.92 | 52.01 | 39.32 | 51.58 | 24.10 | 25.22 | 53.93 | 53.79 | ||||||||||
| Net Income | 42.85 | 93.28 | 85.14 | 88.40 | 113.15 | 176.14 | 64.49 | 70.76 | 91.51 | 91.65 | ||||||||||
| EPS | 7.98 | 17.36 | 15.99 | 16.74 | 21.41 | 33.30 | 12.19 | 13.37 | 17.13 | 17.31 | ||||||||||
| DPS | 10.00 | 10.00 | 20.00 | 5.00 | 25.00 | 15.00 | 18.00 | 0.00 | 21.00 | 18.00 | ||||||||||
| Payout ratio | 1.25 | 0.58 | 1.25 | 0.30 | 1.17 | 0.45 | 1.48 | 0.00 | 1.23 | 1.04 |
THYROCARE Company Updates
FY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2025
Investor Presentation
Jan 23PDF
Oct 23PDF
THYROCARE Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareHospitals & Diagnostic Centres
Compare valuation on Screener
Health CareHospitals & Diagnostic Centres
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Thyrocare Technologies Ltd | 58.81 | 10.20 | 2.07% |
| Max Healthcare Institute Ltd | 106.09 | 13.57 | 0.13% |
| Apollo Hospitals Enterprise Ltd | 113.55 | 13.94 | 0.23% |
| Fortis Healthcare Ltd | 69.06 | 6.25 | 0.14% |
THYROCARE Stock Price Comparison
Compare THYROCARE with any stock or ETFCompare THYROCARE with any stock or ETF
THYROCARE
THYROCARE Shareholdings
THYROCARE Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
High Pledged Promoter Holding
Lower pledged promoter holdings is considered better
A significant proportion of promoter holdings is pledged
THYROCARE Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
THYROCARE Shareholding Pattern
THYROCARE Shareholding History
Foreign Institutions
Mutual Funds Invested in THYROCARE
A list of mutual funds holding the stock, ranked on the basis of Market-cap held which is calculated as the value of stock held in the portfolio divided by its market cap
Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Thyrocare Technologies Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 3.2154% | Percentage of the fund’s portfolio invested in the stock 0.30% | Change in the portfolio weight of the stock over the last 3 months 0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 109/242 (+7) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 2.8811% | Percentage of the fund’s portfolio invested in the stock 1.88% | Change in the portfolio weight of the stock over the last 3 months 0.29% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 21/40 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.6971% | Percentage of the fund’s portfolio invested in the stock 0.35% | Change in the portfolio weight of the stock over the last 3 months 0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 63/103 (-28) |
Compare 3-month MF holding change on Screener
smallcases containing THYROCARE stock
Looks like this stock is not in any smallcase yet.
THYROCARE Events
THYROCARE Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
THYROCARE Upcoming Dividends
No upcoming dividends are available
THYROCARE Past Dividends
Cash Dividend
Ex DateEx DateAug 16, 2024
Final
Final | Div/Share: ₹18.00
Dividend/Share
₹18.00
Ex DateEx Date
Aug 16, 2024
Cash Dividend
Ex DateEx DateApr 20, 2023
Interim
Interim | Div/Share: ₹18.00
Dividend/Share
₹18.00
Ex DateEx Date
Apr 20, 2023
Cash Dividend
Ex DateEx DateMay 11, 2022
Interim
Interim | Div/Share: ₹15.00
Dividend/Share
₹15.00
Ex DateEx Date
May 11, 2022
Cash Dividend
Ex DateEx DateJun 17, 2021
Final
Final | Div/Share: ₹15.00
Dividend/Share
₹15.00
Ex DateEx Date
Jun 17, 2021
Cash Dividend
Ex DateEx DateNov 12, 2020
Interim
Interim | Div/Share: ₹10.00
Dividend/Share
₹10.00
Ex DateEx Date
Nov 12, 2020
THYROCARE Stock News & Opinions
Articles & Videos
Corporate
Thyrocare Technologies allots 996 equity shares under ESOS
Thyrocare Technologies has allotted 996 equity shares under ESOS. With this allotment, the paid up equity share capital has increased to 5,29,94,447 equity shares of Rs 10 each. Powered by Capital Market - Live
6 days agoCapital Market - Live
Spotlight
Thyrocare Tech spurts as Q4 PAT jumps 22% YoY to Rs 22 cr; declares dividend of Rs 21/sh
Profit before tax (PBT) for the March quarter stood at Rs 47.19 crore, marking a robust 106.07% rise from Rs 22.90 crore reported in the same period last year. Total expenses rose 6.92% YoY to Rs 143.93 crore during the quarter. Employee benefits expenses stood at Rs 33.47 crore (up 25.97%), while the cost of materials consumed was at Rs 48.71 crore (up 5.62% YoY) during the period under review. The company's revenue from Diagnostic Testing Services was at Rs 172.69 crore (up 22.38% YoY), while revenue from Imaging Services stood at Rs 13.68 crore (up 7.21% YoY) in Q4 FY25. EBITDA improved 70% YoY to Rs 57.4 crore in the March 2025 quarter from Rs 33.8 crore reported in the corresponding period the previous year. EBITDA margin increased to 31% in Q4 FY25 compared to 22% reported in the corresponding quarter last fiscal year. Meanwhile, the Board has recommended a final dividend of Rs 21 per equity share for FY25, subject to shareholder approval. Thyrocare Technologies is engaged in the healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories, and hospitals in India.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Thyrocare Technologies consolidated net profit rises 22.05% in the March 2025 quarter
Net profit of Thyrocare Technologies rose 22.05% to Rs 21.70 crore in the quarter ended March 2025 as against Rs 17.78 crore during the previous quarter ended March 2024. Sales rose 21.34% to Rs 187.16 crore in the quarter ended March 2025 as against Rs 154.25 crore during the previous quarter ended March 2024. For the full year,net profit rose 29.32% to Rs 91.51 crore in the year ended March 2025 as against Rs 70.76 crore during the previous year ended March 2024. Sales rose 20.19% to Rs 687.35 crore in the year ended March 2025 as against Rs 571.88 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales187.16154.25 21 687.35571.88 20 OPM %30.4921.78 -27.4924.03 - PBDT60.9635.96 70 200.70142.99 40 PBT47.1922.90 106 145.4495.98 52 NP21.7017.78 22 91.5170.76 29 Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Thyrocare Technologies standalone net profit rises 14.14% in the March 2025 quarter
Net profit of Thyrocare Technologies rose 14.14% to Rs 21.95 crore in the quarter ended March 2025 as against Rs 19.23 crore during the previous quarter ended March 2024. Sales rose 23.11% to Rs 173.87 crore in the quarter ended March 2025 as against Rs 141.23 crore during the previous quarter ended March 2024. For the full year,net profit rose 34.64% to Rs 95.78 crore in the year ended March 2025 as against Rs 71.14 crore during the previous year ended March 2024. Sales rose 20.82% to Rs 633.10 crore in the year ended March 2025 as against Rs 524.02 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales173.87141.23 23 633.10524.02 21 OPM %32.0023.78 -29.5425.55 - PBDT59.5835.46 68 197.73137.33 44 PBT47.8025.05 91 151.2198.22 54 NP21.9519.23 14 95.7871.14 35 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Board of Thyrocare Technologies recommends Final Dividend
Thyrocare Technologies announced that the Board of Directors of the Company at its meeting held on 23 April 2025, has recommended a Final dividend of Rs.21 per share (i.e.210%), subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Thyrocare Technologies to discuss results
Thyrocare Technologies will hold a meeting of the Board of Directors of the Company on 23 April 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Thyrocare Tech rises as Q3 PAT jumps 29% YoY to Rs 19 cr
Profit before tax in Q3 FY25 stood at Rs 27.92 crore, up 40.23% from Rs 19.91 crore posted in same quarter last year. Total expenses rose 20.53% YoY to Rs 141.85 crore during the quarter. Cost of materials and services consumed was at Rs 44.79 crore (up 17.84% YoY) while employee benefits expenses stood at Rs 35.09 crore (up 33.12%) during the period under review. The company's revenue from Diagnostic Testing Services was at Rs 151.87 crore (up 24.05% YoY), while revenue from Imaging Services stood at Rs 13.43 crore (up 13.24% YoY) in Q3 FY25. EBITDA improved 32% YoY to Rs 41.6 crore in the December 2024 quarter from Rs 31.6 crore reported in the corresponding period the previous year. EBITDA margin increased to 25% in Q3 FY25 compared to 23% reported in the corresponding quarter last fiscal. Thyrocare Technologies is engaged in the healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories, and hospitals in India.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Thyrocare Technologies grants 2,823 stock options under ESOS
Thyrocare Technologies has approved the grant of 2823 stock options to the eligible employees of the subsidiary company under the Thyrocare Employees Stock Option Scheme. Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Thyrocare Technologies consolidated net profit rises 24.50% in the December 2024 quarter
Net profit of Thyrocare Technologies rose 24.50% to Rs 19.11 crore in the quarter ended December 2024 as against Rs 15.35 crore during the previous quarter ended December 2023. Sales rose 23.14% to Rs 165.92 crore in the quarter ended December 2024 as against Rs 134.74 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales165.92134.74 23 OPM %25.0523.45 - PBDT44.9833.38 35 PBT27.9219.91 40 NP19.1115.35 24 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Thyrocare Technologies to discuss results
Thyrocare Technologies will hold a meeting of the Board of Directors of the Company on 23 January 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 7.06%, vs industry avg of 10.01%
Over the last 5 years, market share decreased from 1.13% to 0.91%
Over the last 5 years, net income has grown at a yearly rate of -3.63%, vs industry avg of 42.91%